Holen Sie sich die Stockscreener-App
4.41
2.32%
0.10
Schlusskurs vom Vortag:
$4.31
Offen:
$4.33
24-Stunden-Volumen:
114.20K
Relative Volume:
0.76
Marktkapitalisierung:
$245.17M
Einnahmen:
$34.16M
Nettoeinkommen (Verlust:
$-98.43M
KGV:
-1.8846
EPS:
-2.34
Netto-Cashflow:
$-119.33M
1W Leistung:
+4.01%
1M Leistung:
-14.20%
6M Leistung:
-25.25%
1J Leistung:
+14.84%
1-Tages-Spanne:
$4.17
$4.5189
1-Wochen-Bereich:
$4.14
$4.5189
52-Wochen-Spanne:
$2.70
$10.25
Foghorn Therapeutics Inc Stock (FHTX) Company Profile
Firmenname
Foghorn Therapeutics Inc
Sektor
Branche
Telefon
617-586-3100
Adresse
500 TECHNOLOGY SQUARE, CAMBRIDGE
Vergleichen Sie FHTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
FHTX
Foghorn Therapeutics Inc
|
4.41 | 245.17M | 34.16M | -98.43M | -119.33M | -2.34 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Foghorn Therapeutics Inc Stock (FHTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-09-03 | Eingeleitet | Jefferies | Buy |
| 2024-08-19 | Eingeleitet | Evercore ISI | Outperform |
| 2023-03-28 | Eingeleitet | BofA Securities | Buy |
| 2023-01-05 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-11-22 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-11-17 | Eingeleitet | Cowen | Outperform |
| 2020-11-17 | Eingeleitet | Goldman | Buy |
| 2020-11-17 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-11-17 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Foghorn Therapeutics Inc Aktie (FHTX) Neueste Nachrichten
Barclays PLC Grows Stock Position in Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World
Foghorn Therapeutics (FHTX) Loses -23.05% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - MSN
Foghorn Therapeutics (FHTX) Upgraded to Strong Buy: Here's What You Should Know - MSN
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Shares Sold by Jane Street Group LLC - Defense World
Foghorn Therapeutics Sets 2025 Strategic Objectives - TipRanks
Foghorn Therapeutics Highlights Program Progress and Strategic Objectives for 2025 - The Manila Times
Barclays PLC Acquires 26,228 Shares of Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Shares Bought by Geode Capital Management LLC - Defense World
Short Interest in Foghorn Therapeutics Inc. (NASDAQ:FHTX) Expands By 6.8% - MarketBeat
More Unpleasant Surprises Could Be In Store For Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) Shares After Tumbling 41% - Simply Wall St
Foghorn Therapeutics announces director resignation - Investing.com India
Foghorn Therapeutics announces director resignation By Investing.com - Investing.com Nigeria
Foghorn Therapeutics Board Member Resignation Announced - TipRanks
State Street Corp Grows Stake in Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World
XTX Topco Ltd Buys Shares of 10,900 Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World
FY2028 EPS Estimate for Foghorn Therapeutics Cut by Analyst - Defense World
HC Wainwright Has Positive Forecast for FHTX FY2024 Earnings - Defense World
Charles Schwab Investment Management Inc. Grows Position in Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World
Wedbush Reduces Earnings Estimates for Foghorn Therapeutics - MarketBeat
HC Wainwright Issues Optimistic Estimate for FHTX Earnings - MarketBeat
Foghorn Therapeutics price target lowered to $13 from $20 at H.C. Wainwright - Yahoo Finance
Short Interest in Foghorn Therapeutics Inc. (NASDAQ:FHTX) Decreases By 9.7% - MarketBeat
Foghorn Therapeutics shares target cut, buy rating on positive outlook By Investing.com - Investing.com Canada
Foghorn Therapeutics (NASDAQ:FHTX) Given New $14.00 Price Target at Jefferies Financial Group - Defense World
Foghorn Therapeutics' (FHTX) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
Foghorn Therapeutics Advances Precision Oncology Pipeline - Yahoo Finance
Foghorn Therapeutics Stock Slides On Cancer Drug Development Halt, But Retail Remains Upbeat - Asianet Newsable
Foghorn Therapeutics' SWOT analysis: chromatin pioneer's stock faces pivotal moment - Investing.com Canada
Jefferies Financial Group Has Lowered Expectations for Foghorn Therapeutics (NASDAQ:FHTX) Stock Price - MarketBeat
Why Foghorn Therapeutics (FHTX) Stock Is Trading Lower - Benzinga
Foghorn Therapeutics Inc. Provides Update on FHD-286 Clinical Development Program and Strategic Priorities - Marketscreener.com
Foghorn shifts focus from AML drug FHD-286 - Investing.com
Foghorn Therapeutics Ends Solo Development of FHD-286 - MarketWatch
Foghorn Therapeutics Provides Update on FHD-286 Clinical Development Program and Strategic Priorities - The Manila Times
Foghorn Therapeutics Halts Key AML Drug Development After Phase 1 Results Fall Short - StockTitan
After Plunging -30.17% in 4 Weeks, Here's Why the Trend Might Reverse for Foghorn Therapeutics (FHTX) - MSN
This Foghorn Therapeutics Insider Reduced Their Stake By 13% - Simply Wall St
Foghorn Therapeutics (FHTX) Upgraded to Buy: Here's Why - MSN
How the (FHTX) price action is used to our Advantage - Stock Traders Daily
Finanzdaten der Foghorn Therapeutics Inc-Aktie (FHTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.81%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):